Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:4450
Name renal cell carcinoma
Definition A renal carcinoma that has_material_basis_in the lining of the proximal convoluted renal tubule of the kidney.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal carcinoma renal cell carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
VHL negative STF-62247 renal cell carcinoma sensitive detail...
CDKN2A loss Palbociclib renal cell carcinoma sensitive detail...
VHL mutant Sunitinib renal cell carcinoma predicted - sensitive detail...
VHL loss Bevacizumab renal cell carcinoma sensitive detail...
VHL loss ELR510444 renal cell carcinoma sensitive detail...
VHL mutant Everolimus renal cell carcinoma sensitive detail...
BRAF V600E Vemurafenib renal cell carcinoma predicted - sensitive detail...
PTEN dec exp Apitolisib renal cell carcinoma no benefit detail...
PIK3CA act mut PTEN dec exp Apitolisib renal cell carcinoma no benefit detail...
VHL inact mut Apitolisib renal cell carcinoma no benefit detail...
PBRM1 inact mut Apitolisib renal cell carcinoma no benefit detail...
PTEN dec exp Everolimus renal cell carcinoma no benefit detail...
PIK3CA act mut PTEN dec exp Everolimus renal cell carcinoma no benefit detail...
VHL inact mut Everolimus renal cell carcinoma predicted - sensitive detail...
PBRM1 inact mut Everolimus renal cell carcinoma no benefit detail...
TSC1 inact mut Everolimus renal cell carcinoma predicted - sensitive detail...
TSC2 inact mut Everolimus renal cell carcinoma predicted - sensitive detail...
TSC1 inact mut Temsirolimus renal cell carcinoma predicted - sensitive detail...
TSC2 inact mut Temsirolimus renal cell carcinoma predicted - sensitive detail...
FGFR1 over exp Sorafenib renal cell carcinoma not applicable detail...
VHL del Regorafenib renal cell carcinoma predicted - sensitive detail...
VHL inact mut Alpha 2 Interferon + Bevacizumab renal cell carcinoma predicted - sensitive detail...
VHL loss BPTES renal cell carcinoma sensitive detail...
VHL loss Telaglenastat renal cell carcinoma sensitive detail...
VHL loss Olaparib + Telaglenastat renal cell carcinoma sensitive detail...
VHL loss BPTES + Olaparib renal cell carcinoma sensitive detail...
VHL mutant Unspecified VEGFR inhibitor renal cell carcinoma no benefit detail...
TSC1 mutant Everolimus renal cell carcinoma conflicting detail...
TSC2 mutant Everolimus renal cell carcinoma conflicting detail...
PTEN loss Everolimus renal cell carcinoma predicted - sensitive detail...
PTEN negative Temsirolimus renal cell carcinoma predicted - sensitive detail...
PTEN negative Everolimus renal cell carcinoma predicted - sensitive detail...
TSC1 mutant Temsirolimus renal cell carcinoma predicted - sensitive detail...
TSC2 mutant Temsirolimus renal cell carcinoma predicted - sensitive detail...
VHL inact mut Belzutifan renal cell carcinoma sensitive detail...
CDKN2A inact mut unspecified immune checkpoint inhibitor renal cell carcinoma not predictive detail...
CDKN2A del unspecified immune checkpoint inhibitor renal cell carcinoma not predictive detail...
VHL inact mut Pazopanib renal cell carcinoma sensitive detail...
EML4 - ALK Alectinib renal cell carcinoma predicted - sensitive detail...
TP53 wild-type VHL inact mut M8891 + Sunitinib renal cell carcinoma sensitive detail...
TP53 wild-type VHL inact mut Cabozantinib + M8891 renal cell carcinoma sensitive detail...
TP53 wild-type VHL inact mut Axitinib + M8891 renal cell carcinoma sensitive detail...
ALK fusion Alectinib renal cell carcinoma predicted - sensitive detail...
ALK rearrange Crizotinib renal cell carcinoma predicted - sensitive detail...
TP53 wild-type BI 907828 renal cell carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00003553 Phase II Cyclophosphamide + Fludarabine Cyclosporine Mycophenolate mofetil Methotrexate Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer Completed USA 0
NCT00184015 Phase Ib/II Bevacizumab + Bortezomib Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) Unknown status USA 0
NCT00301990 Phase II Aldesleukin + Bevacizumab Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status USA 0
NCT00717587 Phase II Sunitinib Girentuximab Motexafin gadolinium Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer Unknown status USA 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00828919 Phase I Axitinib Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials Completed USA | ITA | HUN | GBR | FRA | DEU | CZE 4
NCT00923130 Phase II Bevacizumab + Ixabepilone Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer Completed USA 0
NCT00923845 Phase II Sirolimus Cyclophosphamide + Pentostatin Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer Completed USA 0
NCT01014065 Phase II Sunitinib A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) Completed CAN 0
NCT01026337 Phase 0 Sunitinib Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer Completed USA 0
NCT01120249 Phase III Everolimus S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery (S0931) Active, not recruiting USA 1
NCT01164228 Phase II Sunitinib Gemcitabine Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Completed USA 0
NCT01221506 Phase I Pazopanib Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) Completed USA 0
NCT01283048 Phase I Bevacizumab + Buparlisib Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma Completed USA 0
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA | ITA | FRA | AUS 1
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed USA 0
NCT01361113 Phase II Pazopanib Neoadjuvant Pazopanib in Renal Cell Carcinoma Completed USA 0
NCT01370109 Phase I Sunitinib Cardiovascular Effects of Sunitinib Therapy (CREST) Completed USA 0
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed USA 0
NCT01399918 Phase II Bevacizumab + Everolimus Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) Completed USA 0
NCT01480154 Phase I Hydroxychloroquine + MK2206 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Active, not recruiting USA 0
NCT01510119 Phase Ib/II Everolimus + Hydroxychloroquine Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma Completed USA 0
NCT01517243 Phase II Temsirolimus Sunitinib Phase II Study of Alternating Sunitinib and Temsirolimus Completed USA 0
NCT01543763 Phase I Panobinostat + Pazopanib Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Active, not recruiting USA 0
NCT01575548 Phase III Pazopanib Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting USA 0
NCT01582009 Phase Ib/II Everolimus + Panobinostat Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate Terminated USA 0
NCT01582672 Phase III Sunitinib Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) Terminated USA | ITA | ISR | HUN | GBR | ESP | CZE | CAN 0
NCT01625936 Phase I Bevacizumab NLG207 CRLX101 Plus Bevacizumab in Advanced RCC Completed USA 0
NCT01649180 Phase II Axitinib NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801) Terminated USA 0
NCT01664182 Phase II Sunitinib + Trebananib Pazopanib + Trebananib Sorafenib + Trebananib Trebananib Bevacizumab + Trebananib Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Completed USA 0
NCT01727336 Phase II Axitinib + Dalantercept Axitinib Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma Terminated USA 0
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed USA 0
NCT01767636 Phase II Pazopanib Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer Active, not recruiting USA 0
NCT01806064 Phase I Bevacizumab + Carotuximab A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma Terminated USA | HUN | GBR | CZE 0
NCT01835158 Phase II Cabozantinib Cabozantinib + Sunitinib Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Completed USA 0
NCT01865747 Phase III Everolimus Cabozantinib A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma Completed USA | TUR | SWE | SVK | POL | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | ARG 5
NCT01946789 Phase I Nogapendekin alfa inbakicept A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed USA 0
NCT01984242 Phase II Atezolizumab Sunitinib Atezolizumab + Bevacizumab + Capecitabine A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma Completed USA | ROU | POL | ITA | GBR | FRA | ESP | DEU | CZE 0
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Completed USA 0
NCT02013804 Phase I MEDI0680 A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies Completed USA 0
NCT02014636 Phase I Pazopanib Pembrolizumab Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) Completed USA | GBR 0
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed USA 0
NCT02082210 Phase Ib/II Emibetuzumab + Ramucirumab A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed USA 0
NCT02089334 Phase Ib/II Everolimus + RX-0201 Everolimus Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer Terminated USA 0
NCT02089685 Phase Ib/II Ipilimumab Peginterferon alfa-2b Pembrolizumab Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) Completed 0
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed 1
NCT02133742 Phase I Axitinib + Pembrolizumab A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer Completed USA 0
NCT02164838 Phase I Axitinib VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Completed USA | CAN 0
NCT02170389 Phase I AGS-003 Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer Terminated USA 0
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | NLD 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02187302 Phase II Bevacizumab + NLG207 CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) Completed USA 1
NCT02212730 Phase I Pembrolizumab A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) Terminated 0
NCT02231749 Phase III Ipilimumab + Nivolumab Sunitinib Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Active, not recruiting USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 6
NCT02273752 Phase II Everolimus Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated USA 0
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Completed USA | TUR | POL | NOR | NLD | LBN | ITA | HUN | FRA | ESP | DEU | CAN 2
NCT02406521 Phase I Pazopanib Radium Ra 223 dichloride Sorafenib Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases Completed USA 0
NCT02420821 Phase III Bevacizumab Sunitinib Atezolizumab A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma Completed USA | TUR | POL | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUS 8
NCT02432846 Phase II Sunitinib Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA) Completed USA | SWE | POL | LVA | HUN | GBR | FRA | ESP | CZE 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02471846 Phase I Navoximod Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02493751 Phase I Avelumab + Axitinib A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer Completed USA | GBR 1
NCT02495103 Phase Ib/II Metformin + Vandetanib Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma Terminated USA 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Completed USA | NOR | ESP 0
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated USA 0
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02560012 Phase II Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib Personalized Targeted Inhibitors Treatment in Renal Cell Cancer Terminated USA 0
NCT02576665 Phase I Toca FC + Vocimagene amiretrorepvec A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated USA 0
NCT02596035 FDA approved Nivolumab A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374) Completed USA 0
NCT02599779 Phase II Pembrolizumab A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients Completed CAN 0
NCT02608268 Phase Ib/II Spartalizumab Sabatolimab Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Terminated USA | NLD | ITA | CHE | CAN 4
NCT02608385 Phase I Pembrolizumab Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors Active, not recruiting USA 0
NCT02619253 Phase Ib/II Pembrolizumab + Vorinostat Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma Completed USA 0
NCT02627963 Phase III Sorafenib Tivozanib A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC Completed USA | POL | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL 0
NCT02639182 Phase II AGS16F Axitinib A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma Completed USA | CAN 0
NCT02646319 Phase I Nab-rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated USA 0
NCT02655822 Phase I Atezolizumab + CPI-444 CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Completed USA | CAN | AUS 0
NCT02684006 Phase III Avelumab + Axitinib Sunitinib A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Completed USA | SWE | ROU | NZL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT | AUS 4
NCT02689167 Phase II Sunitinib Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma (SURF) Unknown status FRA 0
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT02718066 Phase Ib/II Chidamide + Nivolumab Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Completed USA 0
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Active, not recruiting USA 0
NCT02724020 Phase II Sapanisertib + Serabelisib Sapanisertib Everolimus MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Completed USA | POL | ITA | GBR | FRA | ESP | CZE | CAN 0
NCT02724878 Phase II Atezolizumab + Bevacizumab + Capecitabine Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Active, not recruiting USA 0
NCT02729194 Phase I Pazopanib Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma Completed USA 0
NCT02762006 Phase I Durvalumab + Tremelimumab Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma Completed USA 0
NCT02781506 Phase II Nivolumab Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer Terminated USA 0
NCT02795819 Phase I Pazopanib + REC-2282 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer Terminated USA 0
NCT02799095 Phase I ALKS 4230 A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors Completed USA | POL | ESP | CAN | BEL | AUS 1
NCT02811861 Phase III Everolimus + Lenvatinib Sunitinib Lenvatinib + Pembrolizumab Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma Active, not recruiting USA | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS 3
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed USA 0
NCT02853331 Phase III Axitinib + Pembrolizumab Sunitinib Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) Active, not recruiting 0
NCT02853344 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Completed 0
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting FRA 0
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT02915783 Phase II Everolimus + Lenvatinib A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease Completed USA 0
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP | CHE 0
NCT02923531 Phase Ib/II Nivolumab + X4P-001 Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma Terminated USA 0
NCT02950766 Phase I Ipilimumab + NeoVax A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma Active, not recruiting USA 0
NCT02952248 Phase I Ezabenlimab A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Completed USA | GBR | CAN 0
NCT02956798 Phase II Pazopanib Pazopanib Vs. Local Therapy for Renal Cancer With Metastases Active, not recruiting USA 0
NCT02962804 Phase II Nivolumab Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) Withdrawn USA 0
NCT02982954 Phase III Ipilimumab + Nivolumab A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920) Completed USA 0
NCT02983045 Phase Ib/II Nivolumab + NKTR-214 A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) Completed USA | POL | ITA | GBR | FRA | ESP | CAN | BEL 0
NCT02992912 Phase II Atezolizumab Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) Active, not recruiting FRA 0
NCT02996110 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC) Completed USA | ITA | ISR | CAN | AUT | AUS 0
NCT03015740 Phase Ib/II Nivolumab + Sitravatinib MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC) Completed USA 0
NCT03024437 Phase Ib/II Atezolizumab + Entinostat Atezolizumab + Bevacizumab + Entinostat Atezolizumab Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Suspended USA 0
NCT03024996 Phase III Atezolizumab A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) Terminated USA | TUR | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 9
NCT03029780 Phase II Ipilimumab + Nivolumab An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma Completed USA | AUS 1
NCT03055013 Phase III Nivolumab Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER) Active, not recruiting USA | ISR | CAN 0
NCT03063762 Phase I Atezolizumab + Obinutuzumab + RO6874281 Atezolizumab + Bevacizumab + Obinutuzumab + RO6874281 Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) Completed USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN 1
NCT03065179 Phase II Ipilimumab + Nivolumab Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients Completed USA 0
NCT03075423 Phase II Sunitinib Ipilimumab + Nivolumab Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (SUNIFORECAST) Active, not recruiting NLD | GBR | FRA | ESP | DEU | CZE | BEL 0
NCT03092856 Phase II Axitinib Axitinib + PF-04518600 Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Active, not recruiting USA 0
NCT03097328 Phase II Sapanisertib Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma Completed USA 0
NCT03109015 Phase II Sunitinib Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET) Completed USA 0
NCT03111901 Phase Ib/II Aldesleukin + Pembrolizumab Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer Withdrawn USA 0
NCT03115801 Phase II Atezolizumab Nivolumab A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Terminated USA 0
NCT03117309 Phase II Ipilimumab + Nivolumab Nivolumab Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma Unknown status USA 0
NCT03126331 Phase II Nivolumab Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients Completed USA 0
NCT03138512 Phase III Ipilimumab + Nivolumab A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) Completed USA | TUR | ROU | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 7
NCT03141177 Phase III Cabozantinib + Ipilimumab + Nivolumab Sunitinib Cabozantinib + Nivolumab A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) Active, not recruiting USA | TUR | ROU | POL | ITA | ISR | GRC | GBR | ESP | DEU | CZE | BRA | AUS | ARG 4
NCT03142334 Phase III Pembrolizumab Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) Active, not recruiting USA | POL | NLD | ITA | IRL | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | AUS | ARG 6
NCT03149822 Phase Ib/II Cabozantinib + Pembrolizumab Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Active, not recruiting USA 0
NCT03163667 Phase II Everolimus + Telaglenastat Everolimus CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC Completed USA 0
NCT03165721 Phase II Guadecitabine A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Terminated USA 0
NCT03172754 Phase Ib/II Axitinib + Nivolumab Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma Active, not recruiting USA 0
NCT03189186 Phase I Pembrolizumab Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas Withdrawn USA 0
NCT03200587 Phase I Avelumab + Cabozantinib Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) Completed USA 0
NCT03203473 Phase II Nivolumab Ipilimumab + Nivolumab Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Active, not recruiting USA 0
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT03207867 Phase II Spartalizumab + Taminadenant A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Terminated USA | NLD | ITA | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | ARG 3
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting POL | NZL | FRA | ESP | AUS 4
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Active, not recruiting USA 0
NCT03241173 Phase Ib/II INCAGN01949 + Ipilimumab INCAGN01949 + Nivolumab INCAGN01949 + Ipilimumab + Nivolumab A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Completed USA 0
NCT03260504 Phase I Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Terminated USA 0
NCT03260894 Phase III Epacadostat + Pembrolizumab Pazopanib + Sunitinib Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC Active, not recruiting USA | TUR | NZL | NOR | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS 6
NCT03264066 Phase II Atezolizumab + Cabozantinib A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors Completed USA | HUN | GBR | DEU | BEL 1
NCT03277352 Phase Ib/II Epacadostat + INCAGN01876 + Pembrolizumab INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Terminated USA 0
NCT03280667 Phase II Denosumab + Pembrolizumab Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD) Active, not recruiting AUS 0
NCT03288532 Phase III Durvalumab Durvalumab + Tremelimumab Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting GBR 0
NCT03289962 Phase I Autogene cevumeran Atezolizumab + Autogene cevumeran A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Active, not recruiting USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL 0
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Terminated USA | CAN 0
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Completed USA 0
NCT03324373 Phase II Everolimus + Lenvatinib Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) Active, not recruiting USA 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03396211 Phase I Nivolumab + Rivoceranib Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Completed USA 0
NCT03401788 Phase II Belzutifan A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) Active, not recruiting USA | GBR | FRA | DNK 0
NCT03425201 Phase Ib/II Cabozantinib + Niraparib Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA) Completed ESP 0
NCT03428217 Phase II Cabozantinib Cabozantinib + Telaglenastat CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic Renal Cell Carcinoma (CANTATA) Completed USA | NZL | ITA | GBR | FRA | ESP | DEU | AUS 0
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Terminated USA 0
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Completed USA | AUS 0
NCT03473730 Phase I Daratumumab Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer Active, not recruiting USA 0
NCT03474497 Phase Ib/II Aldesleukin + Pembrolizumab + Radiotherapy Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Recruiting USA 0
NCT03501381 Phase II Entinostat + Interleukin-12 Interleukin-12 High Dose IL 2 and Entinostat in RCC Active, not recruiting USA 0
NCT03502330 Phase I Cabiralizumab + Nivolumab + Sotigalimab Cabiralizumab + Sotigalimab APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Completed USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Completed USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03541902 Phase II Cabozantinib Sunitinib Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma Active, not recruiting USA 0
NCT03552380 Phase II Entinostat + Ipilimumab + Nivolumab Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma Terminated USA 0
NCT03562507 Phase II CEP-11981 CEP-11981 + Nivolumab Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma Terminated USA 0
NCT03592472 Phase III Pazopanib Abexinostat + Pazopanib A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Recruiting USA | POL | ITA | ESP 2
NCT03595124 Phase II Nivolumab Axitinib + Nivolumab Axitinib A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) Active, not recruiting USA 1
NCT03598816 Phase II Durvalumab + Tremelimumab PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma Withdrawn 0
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy Terminated USA 0
NCT03621982 Phase I Camidanlumab tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Terminated USA | GBR | BEL 0
NCT03628677 Phase I AB154 AB154 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Active, not recruiting USA | AUS 0
NCT03629756 Phase I Etrumadenant + Zimberelimab A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Completed USA 0
NCT03634540 Phase II Belzutifan + Cabozantinib A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) Active, not recruiting USA 0
NCT03635892 Phase II Cabozantinib + Nivolumab A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma Active, not recruiting USA 0
NCT03637803 Phase I MRx0518 + Pembrolizumab MRx0518 and Pembrolizumab Combination Study Terminated USA 0
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Active, not recruiting USA | POL | NZL | NLD | ITA | GBR | FRA | ESP | BRA | ARG 2
NCT03679767 Phase II Retifanlimab A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Completed USA | ROU | POL | ITA | HUN | FRA | ESP | AUT 0
NCT03729245 Phase III Cabozantinib + Sunitinib Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) Terminated USA | NZL | BRA | AUS | ARG 5
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Completed USA 0
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Completed USA 0
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Completed USA | CAN 0
NCT03786796 Phase II Olaparib Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) Recruiting USA 0
NCT03793166 Phase III Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer Active, not recruiting USA 1
NCT03798626 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 Paclitaxel + Ramucirumab + XOMA 052 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 Cabozantinib + XOMA 052 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers Active, not recruiting USA | ITA | ISR | GBR | ESP | DEU | CZE | CAN | BEL | AUS 5
NCT03809624 Phase II INBRX-105 INBRX-105 + Pembrolizumab Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) Terminated USA 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03845166 Phase I XL092 A Study of XL092 in Subjects With Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS 0
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Completed USA 0
NCT03873402 Phase III Nivolumab Ipilimumab + Nivolumab An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer Active, not recruiting USA | ROU | POL | ITA | GRC | FRA | ESP | CZE | AUT | ARG 4
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Completed USA | ESP | CAN | BEL 0
NCT03905889 Phase I Abemaciclib + Sunitinib A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma Terminated USA 0
NCT03926013 Phase I JNJ-63898081 A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors Completed USA | CAN 0
NCT03945773 Phase II Cabozantinib Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (CaboPoint) Active, not recruiting NLD | GBR | FRA | ESP | DEU | CHE | AUT 0
NCT03961698 Phase II Atezolizumab + Bevacizumab + Eganelisib Atezolizumab + Eganelisib + Nab-paclitaxel Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3) Active, not recruiting USA 0
NCT03967522 Phase II Cabozantinib Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases (CABRAMET) Completed FRA 0
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Completed USA 0
NCT03986606 Phase I PSB205 A Study of PSB205 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT03990233 Phase I Effi-DEM Effi-DEM + Ezabenlimab A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Active, not recruiting FRA | BEL 0
NCT03991130 Phase II Aldesleukin + Nivolumab High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma Recruiting USA 0
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Completed USA 0
NCT04022343 Phase II Cabozantinib Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer Active, not recruiting USA 0
NCT04028245 Phase I Canakinumab + Spartalizumab A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1) Recruiting USA 0
NCT04060407 Phase Ib/II CD24Fc + Ipilimumab + Nivolumab CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI) Withdrawn USA 0
NCT04068831 Phase II Avelumab + Talazoparib Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma Completed USA 0
NCT04071223 Phase II Cabozantinib + Radium Ra 223 dichloride Cabozantinib Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study Recruiting USA 0
NCT04074967 Phase Ib/II Ipilimumab + Pexmetinib Nivolumab + Pexmetinib Study of ARRY-614 Plus Either Nivolumab or Ipilimumab Active, not recruiting USA 0
NCT04088500 Phase II Ipilimumab + Nivolumab A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Terminated USA | CAN 0
NCT04090710 Phase II Nivolumab Ipilimumab + Nivolumab SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) Active, not recruiting CAN | AUS 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA 0
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Completed USA 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT04134390 Phase II Cabozantinib Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study (CABOMAYOR) Completed ESP 0
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA | AUS 0
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04262375 Phase II Durvalumab + Oleclumab A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION) Withdrawn CAN 0
NCT04262427 Phase Ib/II Cyclophosphamide + Pembrolizumab The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma (CAPER) Unknown status GBR 0
NCT04267120 Phase II Lenvatinib + Pembrolizumab Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) Active, not recruiting USA 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed AUS 1
NCT04311710 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) Terminated USA | NZL | ITA 0
NCT04322955 Phase II Cabozantinib + Nivolumab CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition (Cyto-KIK) Recruiting USA 0
NCT04337970 Phase Ib/II Axitinib + Talazoparib Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer Active, not recruiting USA 0
NCT04338269 Phase III Cabozantinib Atezolizumab + Cabozantinib A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) Active, not recruiting USA | POL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | AUS | ARG 3
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Completed USA | ESP | DNK 3
NCT04349267 Phase Ib/II BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors Terminated USA | CAN 1
NCT04370509 Phase II Pembrolizumab Axitinib + Pembrolizumab Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery Recruiting USA 0
NCT04393350 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer Recruiting USA 0
NCT04413123 Phase II Cabozantinib + Ipilimumab + Nivolumab Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC Recruiting USA 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04429321 Phase I Ipilimumab + Nivolumab Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary Terminated USA 0
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Terminated USA 0
NCT04438083 Phase I CTX130 A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma Active, not recruiting USA | NLD | CAN | AUS 0
NCT04442126 Phase Ib/II NM21-1480 A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Terminated USA | ESP 1
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Unknown status AUS 2
NCT04489771 Phase II Belzutifan A Study of MK- 6482 in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) Active, not recruiting USA | NLD | ISR | IRL | GRC | GBR | BEL | AUS 1
NCT04495257 Phase I Ipilimumab + Nivolumab + Sotigalimab A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) Active, not recruiting USA 0
NCT04505839 Phase I STP1002 First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors Completed USA 0
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04522323 Phase I Axitinib + MEDI5752 A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma Recruiting USA | FRA | ESP | AUS 0
NCT04540705 Phase Ib/II Axitinib + Nivolumab + NKTR-214 Axitinib + Nivolumab A Study to Evaluate the Triplet Combination of Bempegaldesleukin (Bempeg/NKTR-214) Plus Nivolumab and Axitinib and the Doublet Combination of Nivolumab and Axitinib in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011) Completed USA | FRA | DEU | CAN | BRA | ARG 2
NCT04572451 Phase I BMS-986253 + Nivolumab Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors Recruiting USA 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Active, not recruiting USA | ESP 0
NCT04603365 Phase II Pamiparib + Temozolomide Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer Withdrawn 0
NCT04606381 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) Active, not recruiting USA | GBR | CAN 1
NCT04678908 Phase I HB0025 A Study of Injection HB0025 in Patients With Advanced Solid Tumors Unknown status USA 1
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04696731 Phase I ALLO-647 + Cyclophosphamide + Fludarabine ALLO-316 Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE) Recruiting USA 0
NCT04698213 Phase II Avelumab + Axitinib Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma (TIDE-A) Unknown status ITA 0
NCT04704219 Phase II Lenvatinib + Pembrolizumab Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61) Active, not recruiting USA | TUR | POL | ITA | IRL | HUN | GBR | FRA | ESP | CAN | AUS 3
NCT04707248 Phase I Raludotatug deruxtecan A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors Recruiting USA 1
NCT04714983 Phase I DNX-2440 DNX-2440 for Resectable Colorectal Liver Metastasis Suspended USA 0
NCT04717375 Phase Ib/II BND-22 Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Recruiting USA | ISR | GBR | CAN 0
NCT04736706 Phase III Lenvatinib + Pembrolizumab Lenvatinib + MK-1308A Belzutifan + Lenvatinib + Pembrolizumab A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Active, not recruiting USA | TUR | SWE | ROU | POL | NOR | ITA | IRL | HUN | HRV | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | AUS 15
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT04810078 Phase III Nivolumab Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T) Recruiting USA | TUR | ROU | POL | NZL | ITA | IRL | FRA | FIN | ESP | CZE | BRA | ARG 4
NCT04819373 Phase II BDB001 BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors Completed USA 0
NCT04846920 Phase I Belzutifan A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) Active, not recruiting USA 0
NCT04902040 Phase Ib/II Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Active, not recruiting USA 0
NCT04904302 Phase II Nivolumab + Sitravatinib Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer Active, not recruiting USA 0
NCT04913025 Phase II Pembrolizumab Nivolumab REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE) Recruiting GBR 0
NCT04955743 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Recruiting USA 0
NCT04969315 Phase Ib/II TT-10 TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors Active, not recruiting USA 0
NCT04972981 Phase I ADCT-901 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Active, not recruiting USA | GBR | ESP 0
NCT04981509 Phase II Atezolizumab + Bevacizumab + Erlotinib Testing of Bevacizumab, Erlotinib, and Atezolizumab for Advanced-Stage Kidney Cancer Recruiting USA 0
NCT04987203 Phase III Nivolumab + Tivozanib Tivozanib Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Active, not recruiting USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 3
NCT04991740 Phase I JNJ-78306358 A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors Completed ISR | ESP 0
NCT05012371 Phase II Cabozantinib Everolimus + Lenvatinib Lenvatinib With Everolimus Versus Cabozantinib for Second-Line Treatment of Metastatic Renal Cell Cancer Active, not recruiting USA 0
NCT05024318 Phase II Pembrolizumab NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER) Recruiting AUS 0
NCT05029882 Phase I ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab Recruiting USA | POL | ISR | FRA | ESP | AUS 4
NCT05048212 Phase II Cabozantinib + Ipilimumab + Nivolumab A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases Recruiting USA 0
NCT05052268 Phase Ib/II XTX202 XTX202 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT05061537 Phase I PF-06801591 + PF-07263689 PF-07263689 Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Terminated USA 0
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05092373 Phase I Cabozantinib Atezolizumab + Nab-paclitaxel Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Recruiting USA 0
NCT05101070 Phase Ib/II Pembrolizumab + S-531011 Pembrolizumab S-531011 S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) Recruiting USA 1
NCT05114668 Phase I EVT801 Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours Active, not recruiting FRA 0
NCT05118841 Phase I ZX-4081 Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors Unknown status USA 0
NCT05122546 Phase I Cabozantinib + Nivolumab Cabozantinib + CBM588 + Nivolumab CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Active, not recruiting USA 0
NCT05155033 Phase II Aldesleukin + Pembrolizumab Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma Recruiting USA 0
NCT05176288 Phase II Avelumab + Axitinib + Palbociclib Avelumab, Palbociclib and Axitinib in Advanced RCC (APART) Withdrawn 0
NCT05176483 Phase I Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) Recruiting USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS 0
NCT05188118 Phase I Cabozantinib Nivolumab Everolimus Ipilimumab Lenvatinib Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma Recruiting USA 0
NCT05200559 Phase Ib/II E7777 + Pembrolizumab T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Recruiting USA 0
NCT05229601 Phase I HFB301001 A Study of HFB301001 in Adult Patients With Advanced Solid Tumors Active, not recruiting USA | ESP 0
NCT05238883 Phase I HFB200301 HFB200301 + Tislelizumab A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05239533 Phase II 177Lu-girentuximab + Nivolumab Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer Recruiting USA 0
NCT05239728 Phase III Pembrolizumab Belzutifan + Pembrolizumab A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) Active, not recruiting USA | TUR | SWE | ROU | POL | NZL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BGR | AUS 10
NCT05241561 Phase II Cabozantinib Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients (Cabo-POLARIS) Not yet recruiting FRA 0
NCT05259319 Phase I Atezolizumab + Tiragolumab Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) Recruiting FRA 0
NCT05263050 Phase II Cabozantinib Phase II Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma Recruiting USA 0
NCT05263180 Phase I EMB-09 A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. Recruiting AUS 1
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05293496 Phase I MGC018 + MGD019 A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Completed USA | ESP | BEL | ARG 2
NCT05319015 Phase II Lenvatinib + Pembrolizumab Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus Recruiting USA 0
NCT05323045 Phase I BYON3521 A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 Active, not recruiting NLD | ITA | GBR | BEL 0
NCT05327686 Phase II Axitinib + Pembrolizumab Lenvatinib + Pembrolizumab Ipilimumab + Nivolumab Avelumab + Axitinib Cabozantinib + Nivolumab Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI) Recruiting USA 0
NCT05329532 Phase Ib/II Modi-1 Modi-1 + Pembrolizumab Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY) Recruiting GBR 0
NCT05354323 Phase I NECVAX-NEO1 NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors Recruiting LTU 0
NCT05361720 Phase II Cabozantinib + Nivolumab Ipilimumab + Nivolumab Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Recruiting USA 0
NCT05411081 Phase II Cabozantinib Atezolizumab + Cabozantinib Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial Recruiting USA 0
NCT05417321 Phase Ib/II HB0036 A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors Recruiting USA 1
NCT05462873 Phase I QEQ278 A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL 3
NCT05468697 Phase Ib/II Belzutifan + Palbociclib Belzutifan A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024) Recruiting USA | ISR | AUS 0
NCT05479812 Phase I WTX-124 Pembrolizumab + WTX-124 Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05496595 Phase I DCBY02 DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Terminated USA 0
NCT05585034 Phase I Pembrolizumab + XmAb808 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors Recruiting USA 0
NCT05597839 Phase Ib/II DF9001 DF9001 + Nivolumab Study of DF9001 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05625412 Phase I CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | CAN | AUS | ARG 2
NCT05641545 Phase I IVAC IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients Terminated DEU 0
NCT05678673 Phase III Nivolumab + XL092 Sunitinib Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR-304) Recruiting USA | POL | NLD | ITA | FRA | FIN | ESP | DEU | CZE | BRA | AUS | ARG 4
NCT05703854 Phase Ib/II CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma Recruiting USA 0
NCT05714553 Phase Ib/II Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Recruiting GBR 0
NCT05721222 Phase Ib/II PRO1160 PRO1160 for Advance Solid and Liquid Tumors (PRO1160-001) Recruiting USA 1
NCT05733715 Phase I Pembrolizumab Lenvatinib + Pembrolizumab Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma Recruiting USA 0
NCT05759923 Phase I OATD-02 First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours Recruiting POL 0
NCT05783622 Phase I JANX008 Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies Recruiting USA 0
NCT05785754 Phase I DCSZ11 DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | AUS 2
NCT05789069 Phase I HFB200603 HFB200603 + Tislelizumab A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors Recruiting USA | ITA | ESP 0
NCT05817903 Phase II Nivolumab Axitinib + Nivolumab Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous CR (AxIn) Recruiting ITA 0
NCT05826600 Phase I OMX-0407 A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically Recruiting ESP | BEL 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DNK | CHE 1
NCT05846646 Phase II Pembrolizumab Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC Terminated USA 0
NCT05891171 Phase I AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) Recruiting USA | AUS 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ESP | AUS 0
NCT05920408 Phase Ib/II EXS21546 Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours Terminated FRA | BEL 0
NCT05928806 Phase II Balstilimab + Botensilimab Ipilimumab + Nivolumab Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT) Recruiting USA 0
NCT05931393 Phase II Cabozantinib + Nivolumab Cabozantinib Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC) Recruiting USA 0
NCT05934539 Phase Ib/II ALG.APV-527 ALG.APV-527 First-in-human Study Recruiting USA 0
NCT05947474 Phase I ORB-011 ORB-011 In Patients With Advanced Solid Tumors (ORB) Recruiting USA 0
NCT05949424 FDA approved Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) Not yet recruiting NLD 0
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT06004336 Phase II Pembrolizumab A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs) Recruiting USA 0
NCT06005818 Phase II Pembrolizumab Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) (MRD GATE RCC) Recruiting USA 0
NCT06026410 Phase I Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806 KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) Recruiting USA 0
NCT06034860 Phase I MT-8421 + Nivolumab MT-8421 Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types Terminated USA 0
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06049576 Phase I Camu camu + Ipilimumab + Nivolumab Ipilimumab + Nivolumab Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma Suspended USA 0
NCT06053658 Phase II Nivolumab + Tivozanib Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma Recruiting USA 0
NCT06099782 Phase II MK-3475A Pembrolizumab A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) Active, not recruiting USA | TUR | POL | NZL | FRA | AUS | ARG 3
NCT06108050 Phase I JZP898 + Pembrolizumab JZP898 JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06108479 Phase I DF6215 Study of DF6215 in Patients With Advanced Solid Tumors Recruiting USA | FRA | AUS 0
NCT06120075 Phase I AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) Recruiting USA 0
NCT06132945 Phase I Cabozantinib + Nivolumab A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain Recruiting USA 0
NCT06234605 Phase I HC-7366 Belzutifan + HC-7366 A Study of HC-7366 in Combination With Belzutifan (WELIRE) in Patients With Renal Cell Carcinoma Recruiting USA 0
NCT06240728 Phase I NPX887 A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 Recruiting USA 0
NCT06274437 Phase I BND-35 + Cetuximab BND-35 + Nivolumab BND-35 A Study of BND-35 in Participants With Advanced Solid Tumors Recruiting ISR 0
NCT06284564 Phase II Evolocumab + Nivolumab A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) Recruiting USA 0
NCT06302569 Phase II Enfortumab vedotin-ejfv + Pembrolizumab Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT) Not yet recruiting ITA 0
NCT06307431 Phase II Pembrolizumab mRNA-4157 + Pembrolizumab A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) Recruiting USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | ARG 3
NCT06332755 Phase I LB-LR1109 Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109) Recruiting USA 0
NCT06362369 Phase Ib/II 7HP349 + Ipilimumab + Nivolumab A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Recruiting USA 0
NCT06364631 Phase III Cabozantinib + Nivolumab Ipilimumab + Nivolumab Axitinib + Pembrolizumab Lenvatinib + Pembrolizumab CARE1 Pragmatic Clinical Trial (CARE1) Recruiting FRA 0
NCT06399419 Phase I CBM588 + Ipilimumab + Nivolumab CBM588 in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Recruiting USA 0
NCT06444815 Phase I VET3-TGI Pembrolizumab + VET3-TGI A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) Recruiting USA 0
NCT06514651 Phase I MAQ-001 Ipilimumab + MAQ-001 MAQ-001 in Patients With Advanced Solid Tumors Recruiting FRA 0
NCT06546553 Phase I PF-07826390 PF-06801591 + PF-07826390 A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. Recruiting USA 0
NCT06580938 Phase I PF-07921585 PF-06801591 + PF-07921585 A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer Recruiting USA 0
NCT06582017 Phase I QXL138AM Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma Recruiting USA 0
NCT06626256 Phase I Cyclophosphamide + Fludarabine Aldesleukin + STIL101 STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Not yet recruiting USA 0
NCT06634849 Phase Ib/II PTT-4256 An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. Recruiting AUS 0
NCT06708949 Phase II Ipilimumab + Nivolumab Ipilimumab + Nivolumab and relatlimab-rmbw A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) Not yet recruiting USA 0